A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

What Was Tested

This registered phase 1 trial tested Cagrilintide and Semaglutide.

This clinical study is testing two versions of the study medicine cagrilintide.

The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity.

Participants will receive either cagrilintide version D or cagrilintide version B, and which treatment participants receive is decided by chance.

It had four arms (groups): Cagrilintide B and Placebo Semaglutide I (experimental), Cagrilintide D-Injection site 1 (experimental), Cagrilintide D-Injection site 2 (experimental) and Cagrilintide D-Injection site 3 (experimental).

Participants will receive Cagrilintide B and Placebo semaglutide I subcutaneously once weekly for up to 17 weeks.

Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks.

Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 234 planned participants were the target.

It was open to people of any sex aged from 18 years up to 64 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Aged 18-64 years (both inclusive) at the time of signing informed consent. Body mass index (BMI) between 27.0 and 34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.

The full record lists 3 inclusion and 2 exclusion criteria; among the exclusions: previous participation in study(s) with an amylin analogue. participation is defined as randomisation; any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Because people in this Cagrilintide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Cagrilintide study: the participants and staff both knew the treatment.

It started in 2026-05-18 with completion listed for 2027-05-28.

It ran at 1 site in Germany.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 13 secondary outcomes, for example Number of treatment-emergent adverse events (TEAEs) and Number of treatment-emergent serious adverse events (TESAEs).

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Cagrilintide and Semaglutide in 234 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Cagrilintide compound page and the Semaglutide compound page, all human trials.